Diabetes

Biologic approvals ranged from gene therapies for hemophilia A to a cellular therapy to treat type 1 diabetes.

Study findings shed light on the disproportionate burden of type 2 diabetes (T2D) and colorectal cancer faced by individuals with low socioeconomic status and those of African American race.

Two posters presented at ASHP Midyear 2023 explored the impact of diabetes management interventions among patients with diabetes.

Prior research has shown the association between various socioeconomic variables and lower adherence to diabetic retinopathy screening, but few have elaborated on the patient perspective to understand the reason behind this association.

A new systematic review and meta-analysis found that the risk of type 2 diabetes decreased significantly at walking speeds of 4 km/h or above.

An analysis on the Diabetes Prevention Program in England found it was effective at improving key cardiovascular risk factors, including glycated hemoglobin and excess body weight.

Because of misclassification of diabetes type and the absence of distinction between risk factors, such as birth weight, and diabetes type, uncertainty exists regarding the relationship between obesity and T1D.

The drug, Zepbound, will be available in the United States by the end of 2023.

A poster presented at AMCP Nexus 2023 outlined how a Pharmacy Therapeutics program yielded $7,500 in savings per patient and $3.5 million in savings overall by reducing patients' incretin therapy prescriptions from two to one.

The Omnipod 5 app from Insulet lets users sync their data in one interface and is expected to be released sometime in 2024.

A study published in Primary Care Diabetes pinpoints those at most risk and recommends education to improve the quality of life in diagnosed elderly patients.

Diagnosing diabetes based on traditional criteria has increasingly become unreliable.

Technology may not help teens with the emotional and physical weight of managing the disease, study results show.

GLP-1 receptor agonists, used to manage diabetes, are now being used for obesity in children and adolescents.

A new study from Dartmouth College found that patients maintained healthier blood sugar levels from April to September.

A new study in the New England Journal of Medicine found no significant difference in the number of children who received a T1D diagnosis between those with and without a SARS-CoV-2 infection.

This is the fourth approval for the drug stemming from the EMPOWER clinical trial program.

The American Diabetes Association's 2023 “Children and adolescents: standards of care in diabetes” highlights risk factors and treatment for type 1 and type 2 diabetes.

Presented as part of the Annual Meeting of the European Association for the Study of Diabetes (EASD) meeting, the study was designed as an analysis of the ASPREE trial.

Although investigators found a lack of strong evidence to support CGM programs in community pharmacy settings, studies in ambulatory care settings suggest that these programs are both feasible and beneficial.

Catch up on the latest pharmacy issues and trends with Doug Long, vice president of industry relations at IQVIA.

A study from Bavaria, Germany, found the frequency was higher among boys and children younger than the median age of 6.5 years during the pandemic.

Patients may not experience any early symptoms, making screening especially important.

Patients with diabetes taking a GLP-1 RA of any type had an increased risk of a new GERD diagnosis.

The approval was based on safety and efficacy data from 30 participants in 2 open-label, single-arm studies that received 1 to 3 infusions of donislecel.

Nearly two-thirds of individuals with T2D eventually develop atherosclerotic cardiovascular disease in the United States.

Over 37 million people in the United States have diabetes and are at risk for eye disease, with diabetic retinopathy (DR) being the leading cause of blindness in working-age adults.